First-Quarter 2023 Results: Net Sales of $832.1 Million GAAP Net Income of $54.7 Million; Adjusted EBITDA of $232.9 Million TEPEZZA® Net Sales of $405.3 Million . | May 3, 2023
Fourth-Quarter 2022 Results: Net Sales of $942.0 Million GAAP Net Income of $120.4 Million; Adjusted EBITDA of $357.5 Million; Includes $37.3 Million of Acquired IPR&D and Milestones Expenses
The "Europe Sjogren's Syndrome Market and Competitive Landscape 2021" report has been added to ResearchAndMarkets.com's offering. Europe Sjogren's Syndrome Market and Competitive Landscape 2021, provides